Research programme: bispecific antibodies - Alligator Bioscience/Orion Pharma
Latest Information Update: 28 Sep 2025
At a glance
- Originator Alligator Bioscience; Orion
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for research development in Cancer in Norway
- 28 Sep 2025 No recent reports of development identified for research development in Cancer in Sweden
- 02 Jan 2023 Alligator Bioscience extends research and licensing agreement with Orion Corporation for second bispecific antibody